Overview of Индометацин Софарма

Quick Facts: Indometacin Sopharma

Property	Description
Active Ingredient	Indometacin (INN)
Form	Tablets, Suppositories, Ointment
Pharmacological Class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
Primary Actions	Anti-inflammatory, Analgesic, Antipyretic
Origin	Synthetic, Indole-acetic acid derivative

What is Indometacin Sopharma: General Identity and Composition

Indometacin Sopharma is a medicinal product whose therapeutic effects are derived from the active ingredient Indometacin (INN). This potent, synthetic compound is chemically categorized as an indole derivative. The medication is a single-ingredient product, meaning its actions are attributable solely to the Indometacin compound itself. Indometacin is structurally classified as an indole-acetic acid derivative.

What Type of Medicine is Indometacin Sopharma?

Indometacin Sopharma belongs to the therapeutic group known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a class of medications used to manage pain, fever, and inflammation. Its classification as an NSAID gives it a distinct pharmacological profile centered on three core capabilities: it is anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing). Indometacin serves an established role as a powerful anti-inflammatory and pain-relieving agent. This efficacy makes it a choice for conditions where strong inflammation control is required.

Available Forms and General Therapeutic Purpose

The active ingredient Indometacin is formulated into multiple dosage forms, providing different routes of administration depending on the treatment goal. These forms typically include tablets for oral use, suppositories for rectal administration, and ointment for topical/local application. The availability of multiple forms is a key feature, allowing healthcare professionals to choose the optimal administration route for systemic or localized action.

The overall purpose of Indometacin Sopharma is to provide symptomatic relief by effectively counteracting inflammation, easing associated pain, and reducing fever caused by inflammatory processes.

What side effects are possible with Индометацин Софарма?

Possible Side Effects and Safety Information

The safety profile of Indometacin Sopharma, consistent with its classification as a Non-Steroidal Anti-Inflammatory Drug (NSAID), involves documented adverse reactions classified by frequency and affected organ system in regulatory documents.

Adverse Reaction Frequency and Organ Systems

Side effects are officially classified using standard regulatory frequency categories:

Very Common: Reactions such as headache and dizziness are frequently noted, particularly at the initiation of treatment.
Common: Includes gastrointestinal disturbances (e.g., nausea, dyspepsia, abdominal pain, diarrhea) and edema.
Uncommon/Rare: Less frequent but documented effects involve the Nervous System, Hepatobiliary System (e.g., elevated liver enzymes), and Renal System (e.g., impaired renal function).

Serious Adverse Reactions and Safety Constraints

Official regulatory sources highlight specific serious risks associated with Indometacin. These serious adverse reactions include potentially life-threatening gastrointestinal events such as ulceration, bleeding, and perforation of the stomach or intestines. Additionally, the medicine carries a documented risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, a risk that may increase with the duration of use.

Safety limitations and restrictions are clearly defined in official labeling. The medicine is generally restricted for use in the third trimester of pregnancy and is contraindicated in patients with active or history of recurrent peptic ulcers or severe, uncontrolled heart failure. Furthermore, specific caution is mandated for older adults due to an officially noted increased vulnerability to serious gastrointestinal and renal adverse reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents mandate that individuals seek immediate medical attention right away for any known or suspected overdose of Indometacin Sopharma, requiring contact with emergency services or a certified Poison Control Center. This urgent response is necessary because no specific antidote is known for acute toxicity.

Overdose may present with specific clinical manifestations, primarily involving the Central Nervous System (CNS) and Gastrointestinal (GI) systems. Documented CNS signs include severe headache, confusion, drowsiness, and unsteadiness. GI symptoms include nausea, vomiting (which may contain blood), and diarrhea.

Severe or large overdoses are associated with life-threatening complications, including seizures, coma, acute renal failure, and gastrointestinal perforation. Management is symptomatic and supportive, and may involve procedures such as the administration of activated charcoal or gastric lavage to minimize systemic absorption. Regulatory information notes that elderly patients may exhibit heightened vulnerability to CNS effects, such as confusion, in an overdose context.

Therapeutic Uses of Индометацин Софарма

Quick Facts: Uses of Индометацин Софарма

Addresses symptoms associated with: Moderate to severe rheumatoid arthritis, including chronic disease flares.
Contributes to relief in cases of: Moderate to severe osteoarthritis.
Helps manage symptoms of: Moderate to severe ankylosing spondylitis.
May be used for relief from: Acute painful shoulder (bursitis and/or tendinitis).
Therapeutic role in: Acute gouty arthritis.

What Индометацин Софарма Treats: Main Uses and Benefits

Индометацин Софарма is prescribed by a healthcare provider to manage symptoms associated with several forms of arthritis and related inflammatory conditions. Its primary function is to contribute to the temporary relief of inflammation, stiffness, swelling, and pain.

This medication is specifically indicated for the symptomatic management of:

Rheumatoid Arthritis: Used for moderate to severe cases, including the management of acute exacerbations of chronic disease.
Osteoarthritis and Ankylosing Spondylitis: May offer relief in moderate to severe active stages of these conditions.
Acute Painful Shoulder: The medication may be utilized to address symptoms of inflammation and discomfort related to bursitis or tendinitis in the shoulder area.
Acute Gouty Arthritis: Used to help mitigate the severe joint pain, swelling, and tenderness characteristic of acute gout attacks.

It is important to understand that while this medication assists with symptom management, it does not alter the underlying, progressive course of these chronic diseases. Patients should consult their healthcare provider for comprehensive guidance and monitoring.

Eligibility and Restrictions for Use

The eligibility for using Indometacin Sopharma is strictly defined by regulatory documents, outlining populations for whom use is allowed, restricted, or prohibited. The medicine is primarily indicated for use in adult patients.

Contraindicated Populations (Must Not Use)

Official labeling designates several absolute prohibitions, including:

Patients with documented hypersensitivity to Indometacin or other NSAIDs.
Individuals with a history of aspirin-sensitive asthma or related allergic-type reactions.
Women in the third trimester of pregnancy (30 weeks gestation and later).
Patients receiving treatment for peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Patients with active or a history of recurrent peptic ulcer or gastrointestinal hemorrhage.

Age- and Condition-Based Restrictions

Use in children younger than 14 years is generally not established for the typical rheumatic indications. Elderly patients must use the medicine with greater caution due to increased risk of complications, including serious gastrointestinal events.

Regulatory authorities require avoidance in patients with advanced renal disease or severe uncontrolled heart failure. Use is also not recommended for women who are breastfeeding.

What should I know about interactions with other medicines?

Official Regulatory Information on Interactions

The interaction profile of Indometacin Sopharma is defined by several risks outlined in authoritative government prescribing information, which establish restrictions on co-administration with various medicinal products.

Interaction Type	Interacting Substances/Classes
Absolute Restriction	Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Pentoxifylline, Diflunisal, Analgesic Doses of Aspirin
Clearance Interference	Lithium, Digoxin, Methotrexate, Probenecid
Pharmacodynamic Risk	Anticoagulants (e.g., Warfarin), Platelet Inhibitors (e.g., SSRIs/SNRIs), Corticosteroids

Co-administration with other NSAIDs is prohibited due to a severely increased risk of gastrointestinal adverse events. Similarly, combining with Anticoagulants significantly increases the documented risk of bleeding or hemorrhage.

Indometacin may diminish the effectiveness of Antihypertensive Agents (such as ACE Inhibitors and Diuretics) due to its effects on renal function. Furthermore, Indometacin is documented to impede the renal clearance of substances like Lithium and Methotrexate, leading to elevated plasma concentrations and potential toxicity of those co-administered drugs.

Interaction risks with agents like Diuretics or ACE Inhibitors are officially considered heightened for elderly patients and those with existing renal impairment.

Mechanism of Action

Non-Selective Suppression of Prostaglandin Synthesis

This mechanism is centered on the inhibition of Cyclooxygenase (COX) enzymes (specifically COX-1 and COX-2). The drug blocks the active site of these enzymes, preventing them from converting arachidonic acid into various prostaglandins and thromboxanes. By blocking this initial molecular step in the Arachidonic Acid Cascade, the drug suppresses the production of chemical mediators which are involved in peripheral nociceptor sensitization and local vascular changes.

Modulation of Central Regulatory Pathways

The reduced production of prostaglandins, particularly Prostaglandin E2 (PGE2), extends to systemic effects, influencing central regulatory centers. This action modulates the hypothalamic temperature set point by counteracting PGE2-driven elevation, and influences pain signaling pathways centrally. This dual action influences physiological responses in both localized tissue and core body functions.

Dosage and Administration Information

How Индометацин Софарма is Used: Official Administration Guidelines

Indometacin Sopharma is administered via oral or rectal routes, utilizing immediate-release capsules, extended-release capsules (75 mg), oral suspension, or 50 mg suppositories. The general principle is to use the lowest effective dosage for the shortest duration possible to manage symptoms.

Standard Dosing Regimens

Indication	Starting Dose & Frequency	Maximum Daily Dose	Duration Pattern
Chronic Arthritis (RA, OA, AS)	25 mg two or three times daily	200 mg (IR) or 150 mg (ER)	Increase by 25 mg or 50 mg only at weekly intervals.
Acute Gout	50 mg three times daily (TID)	200 mg	Rapidly reduced to complete cessation once pain is tolerable (typically 3 to 5 days).

Administration Rules and Procedural Notes

Context of Use: Oral forms, including capsules and suspension, must be taken with food, milk, or an antacid to improve tolerability. For patients with persistent night pain due to chronic arthritis, a large portion of the daily dose, up to 100 mg, may be administered at bedtime.

Preparation: Extended-release capsules (75 mg) must be swallowed whole; they are not to be crushed, broken, or chewed. Rectal suppositories are not for oral use.

Special Populations: Indometacin is ordinarily not prescribed for children 14 years of age and under for the approved adult indications. Use in older adults requires particular care, strictly adhering to the principle of using the lowest effective dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Индометацин Софарма

Evidence for Use in Chronic Arthritis and Spondylitis

This section summarizes the structure of the clinical trials that examined study outcomes related to symptoms for conditions marked by functional limitations, specifically Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis. Research exploring these conditions where symptoms may vary in intensity was conducted using Randomized Controlled Trials (RCTs) and long-term comparative trials, with some observation periods extending up to 13 months. The studies primarily focused on adult out-patients with established, active forms of these conditions.

The outcomes related to physical discomfort were monitored throughout the study period. Researchers tracked objective measures such as the articular index (related to joint swelling and tenderness) and grip strength, alongside patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies related to measurements of these physical metrics. Evidence available for these indications often originates from foundational trials.

Evidence for Relief of Acute Gout Attacks

Research exploring short-term symptom changes in acute gout attacks was studied for conditions associated with acute or disruptive episodes. The evidence base relies on short-term Randomized Controlled Trials (RCTs), supported by systematic reviews and meta-analyses. These studies focused exclusively on adult patients experiencing acute flares of gouty arthritis.

In these trials, studies explored outcomes related to physical discomfort and systemic imbalance. Outcomes included tracking pain scores and physician assessments of joint inflammation, such as swelling and redness, as well as the patient's overall global assessment. Research highlights changes measured during the study period which monitored how symptoms evolved in the observed populations during the acute phase.

What is Still Uncertain About Индометацин Софарма’s Research Base

A primary limitation is that many of the foundational trials establishing the initial evidence base are historic. This means comparative evidence is lacking against some currently used therapeutic options available today. Subgroup findings are uncertain; sample sizes were modest, and specific groups were not the primary focus of the research. Long-term effects are not fully established, particularly concerning outcomes related to extended periods of use beyond the time intervals monitored in the clinical trials.

Frequently Asked Questions (FAQ)

Common questions about Индометацин Софарма (FAQ)

Q: In what way does Indometacin Sopharma differ from other NSAIDs, such as Diclofenac?

Indometacin is classified as a potent Non-Steroidal Anti-Inflammatory Drug (NSAID) that is chemically defined as an indole-acetic acid derivative. Regulatory documents strictly advise against combining it with other NSAIDs due to increased risk of side effects.

Q: What does the phrase “short-term symptomatic treatment” mean in the product description?

This official phrasing indicates that the medicine is intended to manage the symptoms of a condition, such as pain, fever, or inflammation, rather than treating the underlying cause. Official guidance consistently emphasizes using the medication for the shortest duration necessary for managing the condition's symptoms.

Q: Is Indometacin Sopharma an analgesic (painkiller) or an anti-inflammatory agent?

Indometacin is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID), which means it possesses three core actions: it is analgesic (relieves pain), anti-inflammatory (reduces inflammation), and antipyretic (reduces fever).

Q: What is the overall safety profile of the drug according to regulatory authorities?

The overall safety profile of Indometacin is defined by official warnings regarding potential risks of serious cardiovascular thrombotic events (such as heart attack or stroke) and serious gastrointestinal adverse events (such as bleeding or ulceration). These risks may increase with the duration of use.

Q: Is a doctor's prescription required to purchase Indometacin Sopharma?

In many jurisdictions, Indometacin is classified as a medicine that is available only with a doctor’s prescription due to the potential for serious adverse risks. The need for a prescription is often required due to the potential for serious adverse risks.

Q: Does Indometacin Sopharma actually help with gout?

Yes. Official regulatory documents specifically list the treatment of Acute Gout Attack as one of the key conditions for which the medicine is officially indicated.

Q: Is it possible to use Indometacin Sopharma for headaches or migraines?

Indometacin has been examined and used in the management of specific headache types, often referred to as Indometacin-responsive headache disorders. It is typically reserved for these specific conditions and is not generally used as a first-line treatment for common headaches.

Q: Is Indometacin Sopharma actually used for certain heart problems?

Yes. Indometacin is officially indicated for closing a hemodynamically significant patent ductus arteriosus (a type of congenital heart condition) in premature infants, using the intravenous form of the medication. This specific use is for a congenital heart condition in infants.

Q: Why do doctors sometimes prescribe Indometacin Sopharma as an ointment?

The availability of the ointment is noted in official sources as one of the multiple dosage forms. This allows for its use where a local (topical) effect is desired, as opposed to an effect throughout the body.

Q: Is there a difference in effect between Indometacin Sopharma tablets and suppositories?

While both forms deliver the active ingredient, the rectal suppository form may be specifically used for patients with chronic arthritis to administer a large portion of the daily dose at bedtime. This administration is intended for relief of persistent night pain.

Q: How long can Indometacin Sopharma be taken without a break?

Official warnings state that the risks of serious adverse events, including gastrointestinal bleeding and cardiovascular events, may increase with the duration of use. The medicine is generally advised to be used for the shortest time period necessary, and long-term use requires careful medical oversight.

Q: How does alcohol interact with Indometacin Sopharma?

Regulatory sources warn that consuming alcohol (ethanol) while taking Indometacin may significantly increase the documented risk of gastrointestinal bleeding, which is a serious side effect of the medication.

Q: Can Indometacin Sopharma be taken with Paracetamol or Ibuprofen?

Regulatory documents state that Indometacin should not be taken with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as Ibuprofen. This combination is prohibited in regulatory documents because it increases the risk of serious gastrointestinal side effects.

Q: Does taking food affect the action of Indometacin Sopharma?

Regulatory guidance states that oral forms must be taken with food, milk, or an antacid primarily to improve gastrointestinal tolerability. This is done to improve the drug's gastrointestinal tolerability.

Q: Is it true that this medicine can affect blood pressure?

Yes. Regulatory documents note that Indometacin may cause or worsen hypertension (high blood pressure). It may also reduce the effectiveness of some blood pressure-lowering medicines, and blood pressure monitoring is mentioned in regulatory guidelines.

Q: Is it true that this drug can affect kidney function?

Official labeling notes a risk of renal toxicity (kidney damage) and advises that use should be avoided in patients with advanced renal disease. The need for renal function monitoring is noted in official guidance.

Q: Can Indometacin Sopharma cause skin reactions?

Official warnings advise that serious skin reactions are a documented risk. The need to discontinue the medication at the first sign of a rash is mentioned in official warnings.

Q: Is there a known link between Indometacin Sopharma and hearing?

Reports have noted a potential association between the medication and adverse effects related to hearing, including tinnitus (ringing in the ears).

Q: How long does Indometacin Sopharma stay in the body?

The time the drug remains active in the body is described by its half-life, which is a pharmaceutical measure. The mean half-life of Indometacin in adults is estimated to be about 4.5 hours.

Q: What are the main topics of research related to Indometacin Sopharma in recent years?

While much of the foundational evidence is historic, more recent scientific research has included topics like the polymorphism (the different chemical structures) of the active ingredient and comparisons against contemporary treatments for established indications.

How should Индометацин Софарма be stored and disposed of?

How to Store and Dispose of Индометацин Софарма (Indomethacin)

Official regulatory guidelines define specific storage requirements for Indomethacin, which vary by pharmaceutical form.

Storage Conditions

Dosage Form	Required Storage Temperature
Oral Capsules/Tablets	Controlled room temperature (20 C to 25 C / 68 F to 77 F)
Rectal Suppositories	Refrigerated temperature (2 C to 8 C / 36 F to 46 F)

All forms must be stored in the original, tightly closed container and protected from light and moisture. The oral suspension must not be frozen.

Safety and Disposal

The medicine must be stored out of the sight and reach of children. Unused or expired Indomethacin should be disposed of according to local regulations and should not be discarded in wastewater or household trash.

Индометацин Софарма